Global E-Cigarette Liquid Market to Reach $37 Billion by 2028

Aug.23.2022
Global E-Cigarette Liquid Market to Reach $37 Billion by 2028
The global e-cigarette liquid market is projected to reach $3.7 billion by 2028, driven by increasing health awareness and demand for safer smoking alternatives.

Market.US has released a research report stating that the global e-cigarette e-liquid market was valued at $1.7 billion in 2020 and is expected to reach $3.7 billion by 2028. The market is projected to grow at a CAGR of 12.8% from 2021 to 2028.


An increasing number of people are turning to safer smoking alternatives as awareness regarding health issues continues to grow. Electronic cigarettes are known to contain lower levels of toxic substances, and offer various flavors such as tobacco, mint, fruit, and nut. This is expected to fuel the consumption of e-cigarette oil.


Electronic cigarettes, unlike traditional tobacco cigarettes, do not contain tobacco and do not produce tar or carbon monoxide. This makes them a safer alternative to smoking. As people become more aware of the harmful effects of smoking on their health, they are more likely to quit, leading to a positive impact on the global sales of electronic cigarettes. This is one of the many reasons why the electronic cigarette industry is thriving.


Global E-liquid Market: Driving Factors


Electronic cigarette liquid is often used as a substitute for traditional tobacco. E-cigarette liquid can be infused with many flavors, providing a fresh and enhanced taste.


Electronic cigarettes are different from traditional cigarettes in that they allow you to inhale fewer toxic substances, reducing the risk of lung disease. These factors are expected to drive growth in the global liquid market. The use of e-liquid in electronic cigarettes helps reduce environmental damage, which is why manufacturers are focusing on liquid e-cigarettes, which are becoming increasingly popular. Green e-cigarettes are an obvious trend, eliminating the environmental burden associated with handling large amounts of cigarette butts.


Furthermore, electronic cigarettes reduce the issue of deforestation and the environmental degradation caused by tobacco production. Compared to traditional smoking, electronic cigarettes provide many advantages to smokers, helping them to reduce their intake of tar and nicotine and leading many to partially or completely quit smoking. These health benefits are driving demand for liquid nicotine in the electronic cigarette market. However, government regulation of e-cigarettes as tobacco products may hinder the future growth of the global e-liquid market.


The main trend in the market: Nicotine salts.


E-cigarettes are considered safer because they do not burn tobacco or produce tar or carbon monoxide. As knowledge about e-cigarettes increases, sales have also been on the rise. This is one of the main factors driving the growth of the e-cigarette oil market. Health authorities and organizations around the world are taking measures to reduce tobacco use, including indoor smoking bans and high taxes. This has encouraged people to use e-cigarettes as a means to quit smoking and has driven market growth.


Leading manufacturers are utilizing social media to promote their products, providing customized flavors, and implementing innovative marketing strategies. Online distribution channels are also being used for e-cigarette accessories and kits. With both open and closed systems becoming increasingly popular, there is an expected increase in global demand. The research report addresses the following questions:


Who are the main players in the electronic e-liquid market? What are the main driving factors for the growth of the electronic e-liquid market? Based on what types of categories is the global electronic e-liquid market classified? What is the expected market size and growth rate of the electronic e-liquid market in the future? In 2021, which distribution channels dominate the electronic e-liquid industry? What criteria are used when selecting companies?


Click to view a sample research report.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to the limitations of the translation ability, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, and foreign related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12